{"id":15,"date":"2022-11-11T10:11:14","date_gmt":"2022-11-11T15:11:14","guid":{"rendered":"https:\/\/arbor.bio\/?page_id=15"},"modified":"2023-01-11T07:14:24","modified_gmt":"2023-01-11T12:14:24","slug":"stay-updated","status":"publish","type":"page","link":"https:\/\/arbor.bio\/?page_id=15","title":{"rendered":"Press Releases"},"content":{"rendered":"<ul id=\"press-repease-filters\"><li><a href=\"#\" class=\"btn-filter 2026\" data-filter=\"2026\">2026<\/a><\/li><li><a href=\"#\" class=\"btn-filter 2025\" data-filter=\"2025\">2025<\/a><\/li><li><a href=\"#\" class=\"btn-filter 2024\" data-filter=\"2024\">2024<\/a><\/li><li><a href=\"#\" class=\"btn-filter 2023\" data-filter=\"2023\">2023<\/a><\/li><li><a href=\"#\" class=\"btn-filter 2022\" data-filter=\"2022\">2022<\/a><\/li><li><a href=\"#\" class=\"btn-filter 2021\" data-filter=\"2021\">2021<\/a><\/li><li><a href=\"#\" class=\"btn-filter 2020\" data-filter=\"2020\">2020<\/a><\/li><li><a href=\"#\" class=\"btn-filter 2019\" data-filter=\"2019\">2019<\/a><\/li><li><a href=\"#\" class=\"btn-filter 2018\" data-filter=\"2018\">2018<\/a><\/li><li><a href=\"#\" class=\"btn-filter active\" data-filter=\"all\">All<\/a><\/li><\/ul><!-- \/press-repease-filters --><ul id=\"press-release-list\" class=\"row justify-content-around\"><li class=\"news-item uncategorized\" data-year=\"uncategorized\"><p class=\"news-date\">Jun 25, 2026<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2244\" title=\"Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria<\/h3><\/a><div class=\"news-excerpt\"><p>PARMA, Italy &amp; CAMBRIDGE, MA, June 25, 2026 \u2014 Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a\u00a0biotechnology company discovering and developing\u00a0the next generation of genetic medicines, today announced a milestone for ABO-101, an investigational gene<a href=\"https:\/\/arbor.bio\/?p=2244\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2026\" data-year=\"2026\"><p class=\"news-date\">May 18, 2026<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2208\" title=\"Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Mathew Pletcher, Ph.D., as Chief Scientific Officer<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 May 18,\u00a02026 &#8211;\u00a0Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mathew Pletcher, Ph.D., as Chief Scientific Officer, succeeding John Murphy, Ph.D., who is retiring\u00a0after five<a href=\"https:\/\/arbor.bio\/?p=2208\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2026\" data-year=\"2026\"><p class=\"news-date\">May 12, 2026<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2206\" title=\"Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 May 12, 2026 &#8211; Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announces the presentation of data demonstrating the first precise in vivo genome editing in the brain using<a href=\"https:\/\/arbor.bio\/?p=2206\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2026\" data-year=\"2026\"><p class=\"news-date\">Apr 27, 2026<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2198\" title=\"Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 April 27, 2026\u00a0&#8211; Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced\u00a0three\u00a0upcoming presentations at the\u00a02026\u00a0American Society of\u00a0Gene\u00a0and\u00a0Cell\u00a0Therapy (ASGCT) 29th Annual Meeting, taking place May\u00a011-15\u00a0in\u00a0Boston,\u00a0Massachusetts.\u00a0 Data presented at ASGCT will\u00a0showcase\u00a0Arbor\u2019s\u00a0expertise\u00a0in<a href=\"https:\/\/arbor.bio\/?p=2198\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">Oct 29, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2141\" title=\"Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines<\/h3><\/a><div class=\"news-excerpt\"><p>INCHEON, Korea \u2013 October 30, 2025 \u2013\u00a0Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&amp;T (KRX: 028260.KS), and managed by Samsung Ventures, today announced an equity investment in Arbor Biotechnologies, Inc., a leading<a href=\"https:\/\/arbor.bio\/?p=2141\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">Oct 6, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2105\" title=\"Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs<\/h3><\/a><div class=\"news-excerpt\"><p>PARMA, ITALY &amp; CAMBRIDGE, MA, USA \u2013 October 6, 2025 &#8211; Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a\u202fnext-generation\u202fbiotechnology company discovering and developing\u202finnovative approaches in\u202fgenetic medicines, today announced an exclusive global collaboration and license agreement<a href=\"https:\/\/arbor.bio\/?p=2105\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">Jul 30, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2063\" title=\"Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1\/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1\/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 July 30, 2025 &#8211; Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the first patient was dosed at Mayo Clinic in the redePHine study evaluating ABO-101, an investigational<a href=\"https:\/\/arbor.bio\/?p=2063\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">Jun 25, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2046\" title=\"Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 June 25, 2025 \u2013 Arbor Biotechnologies\u2122, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dr. Dolsten most recently served<a href=\"https:\/\/arbor.bio\/?p=2046\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">May 19, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2036\" title=\"Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 May 19, 2025 &#8211; Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Don Haut, Ph.D., as Chief Business Officer. In this role, he will be<a href=\"https:\/\/arbor.bio\/?p=2036\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">May 15, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2025\" title=\"Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 May 15, 2025 &#8211; Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the presentation of four posters showcasing Arbor\u2019s commitment to CNS diseases of high unmet need and<a href=\"https:\/\/arbor.bio\/?p=2025\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">May 13, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2021\" title=\"Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 May 13, 2025 &#8211; Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today presents IND- and CTA-enabling data for its lead clinical program, ABO-101 in primary hyperoxaluria type 1 (PH1)<a href=\"https:\/\/arbor.bio\/?p=2021\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">Apr 28, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=2016\" title=\"Arbor Biotechnologies to Present Foundational Data for PH1 and CNS Programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present Foundational Data for PH1 and CNS Programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 April 28, 2025 &#8211; Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced five upcoming presentations at the 2025 American Society of Gene and Cell Therapy (ASGCT) 28th Annual<a href=\"https:\/\/arbor.bio\/?p=2016\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">Mar 18, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1997\" title=\"Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 March 18, 2025 \u2013 Arbor Biotechnologies\u2122, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of<a href=\"https:\/\/arbor.bio\/?p=1997\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2025\" data-year=\"2025\"><p class=\"news-date\">Feb 4, 2025<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1993\" title=\"Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Designations Granted to ABO-101 for the Treatment of Primary Hyperoxaluria Type 1 (PH1) and Upcoming Presentations at the 20th Congress of the International Pediatric Nephrology Association (IPNA)\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Designations Granted to ABO-101 for the Treatment of Primary Hyperoxaluria Type 1 (PH1) and Upcoming Presentations at the 20th Congress of the International Pediatric Nephrology Association (IPNA)<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 February 4, 2025 \u2013 Arbor Biotechnologies\u2122, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare pediatric<a href=\"https:\/\/arbor.bio\/?p=1993\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2024\" data-year=\"2024\"><p class=\"news-date\">Dec 19, 2024<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1812\" title=\"Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1<\/h3><\/a><div class=\"news-excerpt\"><p>CAMBRIDGE, MA \u2013 December 19, 2024 \u2013 Arbor Biotechnologies\u2122, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for<a href=\"https:\/\/arbor.bio\/?p=1812\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2024\" data-year=\"2024\"><p class=\"news-date\">Oct 22, 2024<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1786\" title=\"Arbor Biotechnologies to Highlight New Preclinical Data Supporting Advancement of Pipeline Programs and Knock-In Applicability of Type V Nucleases at Upcoming Medical and Scientific Meetings\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Highlight New Preclinical Data Supporting Advancement of Pipeline Programs and Knock-In Applicability of Type V Nucleases at Upcoming Medical and Scientific Meetings<\/h3><\/a><div class=\"news-excerpt\"><p>Oral presentation at ASN on lead program, ABO-101 for primary hyperoxaluria type 1 (PH1), supporting in vivo proof of pharmacology. On-track for year-end IND\/CTA filing. Oral presentation at ALS One and a poster presentation at ESGCT on lead ALS program<a href=\"https:\/\/arbor.bio\/?p=1786\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2024\" data-year=\"2024\"><p class=\"news-date\">May 9, 2024<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1733\" title=\"Arbor Biotechnologies Presents Data Supporting Clinical Development of ABO-101 and Robust Potential of Platform to Enable Therapeutic Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Presents Data Supporting Clinical Development of ABO-101 and Robust Potential of Platform to Enable Therapeutic Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting<\/h3><\/a><div class=\"news-excerpt\"><p>Presented data which, along with ongoing IND-enabling studies, demonstrate efficacy and pharmacology of ABO-101 in non-human primates (NHPs), supporting continued development as a potential novel gene editing therapy for patients with primary hyperoxaluria type 1 (PH1) Other presentations include preclinical<a href=\"https:\/\/arbor.bio\/?p=1733\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2024\" data-year=\"2024\"><p class=\"news-date\">May 8, 2024<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1730\" title=\"Arbor Biotechnologies Announces Acquisition of Serendipity\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces Acquisition of Serendipity<\/h3><\/a><div class=\"news-excerpt\"><p>Serendipity brings proprietary gene editing assets from the lab of gene editing pioneer Feng Zhang, bolstering Arbor\u2019s diverse toolbox of novel, next-generation editors and expanding potential therapeutic applications in reverse transcriptase-based editing and insertion of large regions of DNA &nbsp;<a href=\"https:\/\/arbor.bio\/?p=1730\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2024\" data-year=\"2024\"><p class=\"news-date\">Apr 22, 2024<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1723\" title=\"Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting<\/h3><\/a><div class=\"news-excerpt\"><p>Oral and poster presentations showcase data demonstrating pipeline progress and continued advancement of Arbor\u2019s pipeline programs toward the clinic Oral presentation with data validating aspects of Arbor\u2019s approach to the discovery and development of unique gene editors, outlines the identification<a href=\"https:\/\/arbor.bio\/?p=1723\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2024\" data-year=\"2024\"><p class=\"news-date\">Mar 12, 2024<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1665\" title=\"Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next Generation Allogeneic CAR T Platform in Autoimmune Disease\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next Generation Allogeneic CAR T Platform in Autoimmune Disease<\/h3><\/a><div class=\"news-excerpt\"><p>Allogene\u2019s AlloCAR T\u2122 Autoimmune Disease Platform Leverages Arbor\u2019s CRISPR Gene-Editing Technology First Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 \u2013 Allogene<a href=\"https:\/\/arbor.bio\/?p=1665\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2024\" data-year=\"2024\"><p class=\"news-date\">Jan 3, 2024<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1584\" title=\"4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases<\/h3><\/a><div class=\"news-excerpt\"><p>Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR\/Cas-based therapeutics for up to six product candidates in CNS Initial product candidate will be developed for a target in amyotrophic lateral<a href=\"https:\/\/arbor.bio\/?p=1584\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">Dec 12, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1564\" title=\"Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor, a biotechnology company discovering and developing the next generation of genetic medicines, will leverage Ginkgo\u2019s R&amp;D services to further optimize Arbor\u2019s novel precision editors Arbor\u2019s portfolio of novel gene editors has significant therapeutic potential because of their unique protospacer<a href=\"https:\/\/arbor.bio\/?p=1564\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">Nov 7, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1510\" title=\"Arbor Biotechnologies Appoints Industry Veteran R. Nolan Townsend to Board of Directors\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Industry Veteran R. Nolan Townsend to Board of Directors<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of R. Nolan Townsend to the Company\u2019s Board of Directors. Mr. Townsend is the Chief Executive Officer of LEXEO Therapeutics, a clinical<a href=\"https:\/\/arbor.bio\/?p=1510\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">Aug 29, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1478\" title=\"Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Ajim Tamboli, CFA, as its Chief Financial Officer. Mr. Tamboli brings over 24 years of health care experience to the role,<a href=\"https:\/\/arbor.bio\/?p=1478\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">Aug 7, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1432\" title=\"Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Deanna M. Petersen, MBA, as its Chief Business Officer. Ms. Petersen joins Arbor from AVROBIO, Inc., where she served as Chief<a href=\"https:\/\/arbor.bio\/?p=1432\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">May 23, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1388\" title=\"Arbor Biotechnologies to Present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day<\/h3><\/a><div class=\"news-excerpt\"><p><a href=\"https:\/\/wsw.com\/webcast\/stifel79\/arbor.b\/2502666\" class=\"btn\" target=\"_blank\" aria-label=\"View Webcast\" rel=\"noopener\">View Webcast<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">May 2, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1330\" title=\"Arbor Biotechnologies Announces Presentations at the 2023 Annual Meeting of the American Society of Gene &#038; Cell Therapy\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces Presentations at the 2023 Annual Meeting of the American Society of Gene &#038; Cell Therapy<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that three abstracts were selected for poster presentation at the upcoming American Society of Gene &amp; Cell Therapy (ASGCT) 26th Annual Meeting being held<a href=\"https:\/\/arbor.bio\/?p=1330\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">Apr 12, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1354\" title=\"Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae, a biotechnology company discovering and developing the next generation of genetic editing medicines, today announced the appointment of Daniel Ory, M.D., as Chief Medical Officer. Dr. Ory joins Arbor from Casma Therapeutics, a Third Rock Ventures start up,<a href=\"https:\/\/arbor.bio\/?p=1354\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">Apr 6, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1310\" title=\"Arbor Biotechnologies to Present at 2023 Cell &#038; Gene Meeting on the Med\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present at 2023 Cell &#038; Gene Meeting on the Med<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that Devyn Smith, Ph.D., Arbor\u2019s Chief Executive Officer and the Chairman of Alliance for Regenerative Medicine, will give welcoming remarks and present at the<a href=\"https:\/\/arbor.bio\/?p=1310\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">Jan 11, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1120\" title=\"Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae (Arbor) today announced the expansion of an existing strategic collaboration covering in vivo genetic medicines by which Vertex Pharmaceuticals Incorporated (Vertex) will receive rights to Arbor\u2019s novel precision editing technology for up to three diseases. Under the terms<a href=\"https:\/\/arbor.bio\/?p=1120\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2023\" data-year=\"2023\"><p class=\"news-date\">Jan 4, 2023<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=1037\" title=\"Arbor Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief Executive Officer, Devyn Smith, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Oct 20, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=441\" title=\"Arbor Biotechnologies&#8217; CEO Devyn Smith, Ph.D., Elected as Chairman of the Alliance for Regenerative Medicine\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies&#8217; CEO Devyn Smith, Ph.D., Elected as Chairman of the Alliance for Regenerative Medicine<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief Executive Officer, Devyn Smith, Ph.D., has been elected as the Chairman of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Oct 4, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=438\" title=\"Arbor Biotechnologies to Participate in the 2022 Cell &#038; Gene Meeting on the Mesa\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Participate in the 2022 Cell &#038; Gene Meeting on the Mesa<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that senior management will participate in a panel discussion and present a corporate overview at the 2022 Cell &#038; Gene Meeting on the Mesa.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Sep 22, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=433\" title=\"Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September and October.<\/p>\n<p><a class=\"btn\" href=\"https:\/\/wsw.com\/webcast\/jeff259\/register.aspx?conf=jeff259&#038;page=arbor.b&#038;url=https:\/\/wsw.com\/webcast\/jeff259\/arbor.b\/2212770\" target=\"_blank\" rel=\"noopener\">Webcast Link<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Sep 12, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=430\" title=\"Arbor Biotechnologies Named One of Fierce Biotech&#8217;s &#8220;Fierce 15&#8221; Companies of 2022\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Named One of Fierce Biotech&#8217;s &#8220;Fierce 15&#8221; Companies of 2022<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup> today announced that Fierce Biotech has named it as one of 2022&#8217;s &#8220;Fierce 15&#8221; biotechnology companies, designating it as one of the most promising early stage biotechnology companies in the industry.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Sep 1, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=427\" title=\"Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September.<\/p>\n<p><a class=\"btn\" href=\"https:\/\/event.webcasts.com\/starthere.jsp?ei=1566106&#038;tp_key=a2b8812f58&#038;tp_special=8\" target=\"_blank\" rel=\"noopener\">Webcast Link<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Aug 25, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=423\" title=\"Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Aug 2, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=420\" title=\"Arbor Biotechnologies Appoints Lee Ann Marchionna as Chief People Officer\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Lee Ann Marchionna as Chief People Officer<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Lee Ann Marchionna, MBA, to the newly created role of Chief People Officer. Ms. Marchionna joins Arbor<sup>&reg;<\/sup> with more than 25 years of experience in Human Resources, having led organizational effectiveness initiatives as well as establishing talent, culture, and engagement practices for both public and private life sciences companies.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">May 3, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=417\" title=\"Arbor Biotechnologies to Present at the Bank of America Global Healthcare Conference\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present at the Bank of America Global Healthcare Conference<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in the upcoming Bank of America Global Healthcare Conference in Las Vegas, NV.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">May 2, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=414\" title=\"Arbor Biotechnologies Announces Presentations at 2022 Annual Meeting of the American Society of Gene &#038; Cell Therapy\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces Presentations at 2022 Annual Meeting of the American Society of Gene &#038; Cell Therapy<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced upcoming preclinical data presentations at the 25th Annual Meeting of the American Society of Gene &#038; Cell Therapy (ASGCT) being held May 16-19, 2022, in Washington, D.C.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Feb 22, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=411\" title=\"Arbor Biotechnologies Appoints Steven J. Favaloro as Chief Financial Officer\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Appoints Steven J. Favaloro as Chief Financial Officer<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Steven J. Favaloro as Chief Financial Officer.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Feb 8, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=408\" title=\"EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs<\/h3><\/a><div class=\"news-excerpt\"><p>EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor<sup>&reg;<\/sup>\u2019s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Jan 10, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=399\" title=\"Arbor Biotechnologies to Present at the 40th Annual J.P. Morgan Healthcare Conference\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present at the 40th Annual J.P. Morgan Healthcare Conference<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2022\" data-year=\"2022\"><p class=\"news-date\">Jan 4, 2022<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=911\" title=\"TCR2 Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">TCR2 Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies<\/h3><\/a><div class=\"news-excerpt\"><p>TCR<sup>2<\/sup> Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, and Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the two companies have entered into a strategic research collaboration and non-exclusive license agreement focused on the further development of a defined set of allogeneic TRuC-T cell therapies.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2021\" data-year=\"2021\"><p class=\"news-date\">Nov 9, 2021<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=914\" title=\"Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies<sup>&reg;<\/sup>, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the completion of an oversubscribed and up-sized $215 million Series B financing.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2021\" data-year=\"2021\"><p class=\"news-date\">Aug 24, 2021<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=917\" title=\"Vertex and Arbor Establish New Partnership\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Vertex and Arbor Establish New Partnership<\/h3><\/a><div class=\"news-excerpt\"><p>The new agreement will enhance efforts in developing ex vivo engineered cell therapies using Arbor<sup>&reg;<\/sup>&#8216;s proprietary CRISPR gene editing technology for select diseases.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2021\" data-year=\"2021\"><p class=\"news-date\">Jun 23, 2021<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=920\" title=\"Arbor Strengthens Focus on Therapeutics with Key Additions to Leadership Team\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Strengthens Focus on Therapeutics with Key Additions to Leadership Team<\/h3><\/a><div class=\"news-excerpt\"><p>Pam Stetkiewicz, Ph.D., named Chief Operating Officer, and Kathryn McCabe, Ph.D., joins as SVP, Head of Business Development<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2021\" data-year=\"2021\"><p class=\"news-date\">Jun 21, 2021<\/p><div class=\"news-content\"><a href=\"https:\/\/www.globenewswire.com\/en\/news-release\/2021\/06\/21\/2250182\/0\/en\/Arbor<sup>\u00ae<\/sup>-Biotechnologies-to-Present-at-the-Raymond-James-Human-Health-Innovation-Conference.html\" title=\"Arbor Biotechnologies to Present at the Raymond James Human Health Innovation Conference\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present at the Raymond James Human Health Innovation Conference<\/h3><\/a><div class=\"news-excerpt\"><p>Devyn Smith, CEO, and other members of Arbor<sup>&reg;<\/sup>\u2019s management team will participate in one-on-one meetings with life science investors at the event.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2021\" data-year=\"2021\"><p class=\"news-date\">Jun 1, 2021<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=928\" title=\"Arbor Biotechnologies to Present at the Evercore ISI GenomeRx Emerging Therapeutics Conference and the Jefferies Virtual Healthcare Conference\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies to Present at the Evercore ISI GenomeRx Emerging Therapeutics Conference and the Jefferies Virtual Healthcare Conference<\/h3><\/a><div class=\"news-excerpt\"><p>Devyn Smith, CEO, and other members of Arbor<sup>&reg;<\/sup>\u2019s management team will participate in one-on-one meetings with life science investors at both events.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2021\" data-year=\"2021\"><p class=\"news-date\">May 27, 2021<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=931\" title=\"Arbor Continues to Build Therapeutic Focus with Key Scientific Leaders\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Continues to Build Therapeutic Focus with Key Scientific Leaders<\/h3><\/a><div class=\"news-excerpt\"><p>John Murphy, Ph.D., named Chief Scientific Officer and Greg Hoffman, Ph.D., joins as VP, Discovery &#038; Platform<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2021\" data-year=\"2021\"><p class=\"news-date\">Apr 1, 2021<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=936\" title=\"Arbor Announces Devyn Smith, Ph.D., to Join as CEO\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Announces Devyn Smith, Ph.D., to Join as CEO<\/h3><\/a><div class=\"news-excerpt\"><p>Dr. Smith brings significant cell and gene therapy development and platform experience from his 20+ year career at Sigilon Therapeutics and Pfizer Inc.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2021\" data-year=\"2021\"><p class=\"news-date\">Mar 3, 2021<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=941\" title=\"Arbor Announces Addition of Mark Angelino to Board of Directors\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Announces Addition of Mark Angelino to Board of Directors<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae announced today the appointment of Mark D. Angelino, co-founder and former Chief Operating Officer of Generation Bio, to its Board of Directors. Mark brings significant company building and product development experience to the Arbor Board, given his expertise<a href=\"https:\/\/arbor.bio\/?p=941\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2020\" data-year=\"2020\"><p class=\"news-date\">Dec 23, 2020<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=944\" title=\"Arbor and Lonza Announce Licensing Deal\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor and Lonza Announce Licensing Deal<\/h3><\/a><div class=\"news-excerpt\"><p>The new agreement will provide Lonza with access to Arbor<sup>&reg;<\/sup>&#8216;s gene editing technology<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2020\" data-year=\"2020\"><p class=\"news-date\">Sep 29, 2020<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=947\" title=\"Vor Biopharma and Arbor Biotechnologies Announce Collaboration\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Vor Biopharma and Arbor Biotechnologies Announce Collaboration<\/h3><\/a><div class=\"news-excerpt\"><p>Vor will use Arbor<sup>&reg;<\/sup>&#8216;s proprietary gene editing technologies to develop therapies for the treatment of blood cancers.<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2019\" data-year=\"2019\"><p class=\"news-date\">Sep 25, 2019<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=954\" title=\"Arbor Biotechnologies Announces Issuance of U.S. Patent for CRISPR-Cas13d\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces Issuance of U.S. Patent for CRISPR-Cas13d<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae, an early-stage life sciences company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,392,616 entitled, &#8220;CRISPR RNA Targeting Enzymes and Systems and Uses Thereof.&#8221; The patent is based on Arbor&#8217;s<a href=\"https:\/\/arbor.bio\/?p=954\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2019\" data-year=\"2019\"><p class=\"news-date\">Jul 9, 2019<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=959\" title=\"Arbor Biotechnologies Selected for MIT STEX25\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Selected for MIT STEX25<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae (Arbor), an early-stage biodiscovery company, announced today that it has been selected for STEX25, an MIT Startup Exchange featuring 25 industry-ready startups that are poised for significant growth. Arbor joins eight other companies chosen for the current session.<a href=\"https:\/\/arbor.bio\/?p=959\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2019\" data-year=\"2019\"><p class=\"news-date\">Jan 3, 2019<\/p><div class=\"news-content\"><a href=\"https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-and-arbor-biotechnologies-establish-collaboration\" title=\"Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies<\/h3><\/a><div class=\"news-excerpt\"><p>Multi-year research collaboration funded by Vertex using Arbor<sup>&reg;<\/sup>\u2019s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases<\/p>\n<\/div><\/div><\/li><li class=\"news-item 2019\" data-year=\"2019\"><p class=\"news-date\">Jan 3, 2019<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=968\" title=\"Arbor Biotechnologies Announces New Type V CRISPR-Cas System Discoveries and Addition to its Board\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Announces New Type V CRISPR-Cas System Discoveries and Addition to its Board<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae (Arbor), an early-stage life sciences company, today announced significant milestones including the discovery of multiple new type V CRISPR-Cas systems, published in the journal Science, and the appointment of Paul Meister to the Arbor Board of Directors. Earlier<a href=\"https:\/\/arbor.bio\/?p=968\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><li class=\"news-item 2018\" data-year=\"2018\"><p class=\"news-date\">Jul 23, 2018<\/p><div class=\"news-content\"><a href=\"https:\/\/arbor.bio\/?p=973\" title=\"Arbor Biotechnologies Strengthens Leadership Team Names Daniel Maarten Janse Chief Business Officer\" class=\"news-wrap-link blockLink\" target=\"_blank\"><h3 class=\"news-title\">Arbor Biotechnologies Strengthens Leadership Team Names Daniel Maarten Janse Chief Business Officer<\/h3><\/a><div class=\"news-excerpt\"><p>Arbor Biotechnologies\u00ae, an early stage biodiscovery company, today announced it has strengthened its leadership team with the appointment of Daniel Maarten Janse as Chief Business Officer. &#8220;Daniel&#8217;s strategic focus on business development and his extensive experience in early stage biodiscovery<a href=\"https:\/\/arbor.bio\/?p=973\" class=\"read-more\">Read More<\/a><\/p>\n<\/div><\/div><\/li><\/ul><p><a class=\"btn\" href=\"#\" title=\"Show More\" class=\"btn\" id=\"loadMore\">Show More<\/a> <a class=\"btn\" href=\"#\" title=\"Show Less\" class=\"btn\" id=\"showLess\">Show Less<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":8,"comment_status":"closed","ping_status":"closed","template":"page-sectional-narrow.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-15","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Press Releases - Arbor Biotechnologies<\/title>\n<meta name=\"description\" content=\"At Arbor&reg; Biotech, we are building on our founders&#039; vision to revolutionize how genetic disease is treated.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/arbor.bio\/stay-updated\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Press Releases - Arbor Biotechnologies\" \/>\n<meta property=\"og:description\" content=\"At Arbor&reg; Biotech, we are building on our founders&#039; vision to revolutionize how genetic disease is treated.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/arbor.bio\/stay-updated\/\" \/>\n<meta property=\"og:site_name\" content=\"Arbor Biotechnologies\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-11T12:14:24+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/stay-updated\\\/\",\"url\":\"https:\\\/\\\/arbor.bio\\\/stay-updated\\\/\",\"name\":\"Press Releases - Arbor Biotechnologies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/arbor.bio\\\/#website\"},\"datePublished\":\"2022-11-11T15:11:14+00:00\",\"dateModified\":\"2023-01-11T12:14:24+00:00\",\"description\":\"At Arbor&reg; Biotech, we are building on our founders' vision to revolutionize how genetic disease is treated.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/arbor.bio\\\/stay-updated\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/arbor.bio\\\/stay-updated\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/stay-updated\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/arbor.bio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press Releases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/#website\",\"url\":\"https:\\\/\\\/arbor.bio\\\/\",\"name\":\"Arbor Biotechnologies\",\"description\":\"Our journey began at the genome.  It continues with the patient,\",\"publisher\":{\"@id\":\"https:\\\/\\\/arbor.bio\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/arbor.bio\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/#organization\",\"name\":\"Arbor Biotechnologies\",\"url\":\"https:\\\/\\\/arbor.bio\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/arbor.bio\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/arbor.bio\\\/wp-content\\\/uploads\\\/cropped-Transparent-Color-Logo.png\",\"contentUrl\":\"https:\\\/\\\/arbor.bio\\\/wp-content\\\/uploads\\\/cropped-Transparent-Color-Logo.png\",\"width\":1286,\"height\":1080,\"caption\":\"Arbor Biotechnologies\"},\"image\":{\"@id\":\"https:\\\/\\\/arbor.bio\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Press Releases - Arbor Biotechnologies","description":"At Arbor&reg; Biotech, we are building on our founders' vision to revolutionize how genetic disease is treated.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/arbor.bio\/stay-updated\/","og_locale":"en_US","og_type":"article","og_title":"Press Releases - Arbor Biotechnologies","og_description":"At Arbor&reg; Biotech, we are building on our founders' vision to revolutionize how genetic disease is treated.","og_url":"https:\/\/arbor.bio\/stay-updated\/","og_site_name":"Arbor Biotechnologies","article_modified_time":"2023-01-11T12:14:24+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/arbor.bio\/stay-updated\/","url":"https:\/\/arbor.bio\/stay-updated\/","name":"Press Releases - Arbor Biotechnologies","isPartOf":{"@id":"https:\/\/arbor.bio\/#website"},"datePublished":"2022-11-11T15:11:14+00:00","dateModified":"2023-01-11T12:14:24+00:00","description":"At Arbor&reg; Biotech, we are building on our founders' vision to revolutionize how genetic disease is treated.","breadcrumb":{"@id":"https:\/\/arbor.bio\/stay-updated\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/arbor.bio\/stay-updated\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/arbor.bio\/stay-updated\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/arbor.bio\/"},{"@type":"ListItem","position":2,"name":"Press Releases"}]},{"@type":"WebSite","@id":"https:\/\/arbor.bio\/#website","url":"https:\/\/arbor.bio\/","name":"Arbor Biotechnologies","description":"Our journey began at the genome.  It continues with the patient,","publisher":{"@id":"https:\/\/arbor.bio\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/arbor.bio\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/arbor.bio\/#organization","name":"Arbor Biotechnologies","url":"https:\/\/arbor.bio\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/arbor.bio\/#\/schema\/logo\/image\/","url":"https:\/\/arbor.bio\/wp-content\/uploads\/cropped-Transparent-Color-Logo.png","contentUrl":"https:\/\/arbor.bio\/wp-content\/uploads\/cropped-Transparent-Color-Logo.png","width":1286,"height":1080,"caption":"Arbor Biotechnologies"},"image":{"@id":"https:\/\/arbor.bio\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/pages\/15","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/arbor.bio\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15"}],"version-history":[{"count":0,"href":"https:\/\/arbor.bio\/index.php?rest_route=\/wp\/v2\/pages\/15\/revisions"}],"wp:attachment":[{"href":"https:\/\/arbor.bio\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}